MARIETTA, Ga., June 11, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of three newly issued patents related to tissue allografts derived from the placenta.
The U.S Patent Office has issued to MiMedx® U.S. Patent Number 8,409,626, "Placental Tissue Grafts" with a grant date of April 2, 2013. The U.S. Patent Office has also issued to MiMedx® U.S. Patent Number 8,460,715, "Placental Tissue Grafts" and U.S. Patent Number 8,460,716, "Method for Applying a Label to a Placental Tissue Graft", both with a grant date of June 11, 2013. The new patents relate to the Company's placental tissue allografts, including AmnioFix® and EpiFix® brand allografts.
Human amnion/chorion tissue is rich in cytokines and growth factors known to promote wound healing; however, preservation of the biological activities of therapeutic allografts during processing is challenging. The dehydrated human amnion/chorion membrane tissue allografts ("dHACM") resulting from the MiMedx proprietary PURION® process have solved this challenge. PURION® processed dHACM retains biologically active growth factors and regulatory factors that are in part responsible for its clinical effectiveness in wound healing and other applications.
"We are pleased to have been granted three new patents during the second quarter of this year. These three newly issued patents now give us a total of eight dHACM-based U.S. patents that have been issued to MiMedx®," said Parker H. "Pete" Petit, Chairman and CEO. "We are also pleased that our allografts from our proprietary AmnioFix® and EpiFix® technologies are continuing to gain excellent reception among the physician community and the private and public sector insurance carriers.""We are being extremely diligent about the protection of our AmnioFix® and EpiFix® intellectual property. At our direction, our patent counsel is currently reviewing certain issues that have come to our attention related to potential infringement from competing products on our intellectual property. We will use all of the legal remedies and means available to be certain that our intellectual property is respected," added Petit.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV